Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:00:36.313Z.
Consensus retrieved: 2026-10-06T09:14:05.790Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:00:36.313Z.
Quote observation: 2026-10-06T14:00:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6c02d81e284155bdcda1783dec911e9c0a395e203238f61c1cccf60d236910ce
Forward PE Ratio (N/A) = Dated Quote Price ($172.68) / Consensus Forward EPS ($-2.70)
FORWARD PE RATIO
N/A
Axsome Therapeutics, Inc.
Market Cap
$8.89B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | $8.89B | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $8.81B | 268.64 |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.74B | N/A |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.72B | N/A |
| Insulet Corp. (PODD)vs › | $9.34B | 20.73 |
| Bruker Corporation (BRKRP)vs › | $9.35B | 219.64 |
| Oscar Health, Inc. (OSCR)vs › | $8.40B | 16.97 |
| Bruker Corporation (BRKR)vs › | $9.65B | 29.89 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.70B | 43.23 |
| Henry Schein, Inc. (HSIC)vs › | $9.73B | 15.87 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $172.68, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.70 | $-3.79 – $-1.71 | 15 | n/m |
| 2027-12-31 | $4.51 | $-4.05 – $9.55 | 14 | 38.3x |
| 2028-12-31 | $12.15 | $-3.48 – $24.95 | 17 | 14.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
